The role of xenografting in pediatric brain tumor research with specific emphasis on medulloblastoma/primitive neuroectodermal tumors of childhood

In Vivo

Volumn 17, Issue 4, 2003, Pages 329-342

  Sterling Levis, Katy ^a   White, Les ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Brain tumors; Chemotherapy.; Heterotransplantation; Nude mice; Pediatric; Xenografting

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 O BENZYLGUANINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; DIAZIQUONE; EDOTECARIN; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; IFOSFAMIDE; IRINOTECAN; LYMPHOCYTE ANTIBODY; MATRIGEL; MELPHALAN; METHOTREXATE; NITROSOUREA DERIVATIVE; PROCARBAZINE; RADIOSENSITIZING AGENT; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ASSAY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CHILDHOOD CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; DEATH; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TRANSPORT; EXTRACELLULAR MATRIX; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NEUROSURGERY; NEUTRON CAPTURE THERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; SUBCUTANEOUS TISSUE; TUMOR GROWTH; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

EID: 0043124299     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (172)

1. Silverberg E: Cancer statistics. Cancer 33: 9-25, 1983.
2. Finlay JL and Goins SC: Brain tumors in children, III. Advances in chemotherapy. Am J Ped Hematol Oncol 9: 264-71, 1987.
3. Loeffler JS, Kretschmar CS, Sallan SE, LaVally BL, Winston KR, Fischer EG and Tarbell NJ: Pre-radiation chemotherapy for infants and poor prognosis children with medulloblastoma. Int J Rad Onc Biol Phys 15: 177-81, 1988.
4. Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, Cohen BH, D'Angio G, Kramer ED and Zimmerman RA: Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 74: 433-40, 1991.
5. Albright AL: Pediatric brain tumors. CA-A Cancer J for Clinicians 43: 272-88, 1993.
6. Pollack IF: Brain tumors in children. N Engl J Med 331: 1500-7, 1994.
7. Bruggers CS: Chemotherapy in pediatric brain tumors. Phlo Forum 2: 1-6, 1995.
8. Shapiro WR, Yung WA, Basler GA and Shapiro JR: Heterogenous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro. Cancer Treat Rep 65: 55-9, 1981.
9. Bullard DE, Schold SC, Bigner SH and Bigner DD: Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40: 410-27, 1981.
10. Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Wikstrand CJ, Halperin EC and Bigner DD: Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropath Exp Neuro 44: 592-605, 1985.
11. Friedman HS, Colvin OM, Skapex SX, Ludeman SM, Elion GB, Schold SC Jr, Jacobsen PF, Muhlbaier LH and Bigner DD: Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189-95, 1988.
12. Wasson JC, Saylors III RL, Zeltzer P, Friedman HS, Bigner SH, Burger PC, Bigner DD, Look AT, Douglass EC and Brodeur GM: Oncogene amplification in pediatric tumors. Cancer Res 50: 2987-90, 1990.
13. Paulus W and Peiffer J: Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64: 442-7, 1989.
14. Goldie JH and Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-31, 1979.
15. Brightman MW: Morphology of blood-brain interfaces. Experimental Eye Research (Suppl): 1-25, 1977.
16. Greig NH: Optimizing drug delivery to brain tumors. Cancer Treat Rev 14: 1-28, 1987.
17. Schold SC Jr, Herndon JE, Burger PC, Halperin EC, Vick NA, Cairncross JG, Macdonald DR, Dropcho EJ, Morawetz R and Bigner DD: Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. J Clin Oncol 11: 77-83, 1993.
18. Ali-Osman F, Rosenblum ML, Giannini DD and Levin VA: Potential antiglioma activity of 9-Hydroxy-2-N-methylellipticine as determined by pharmacological and human tumor clonogenic cell studies. Cancer Res 45: 2988-92, 1985.
19. Ali-Osman F: Prediction of clinical response to therapy of adult and pediatric brain tumor patients by chemosensitivity testing in the capillary tumor clonogenic cell assay. In: Packer RJ, Bleyer WA, Pochedly C, eds. Pediatric Neurooncology 3. Harwood Academic Publishers, p. 219-229, 1992.
20. Dodion F, Sanders C, Georges P and Kennis Y: In vitro chemosensitivity of brain tumors to cisplatin and its analogues, proplatin and carboplatin. Cancer Chemother Pharmacol 22: 80-2, 1988.
21. Unsgaard G, Helseth E, Vik R and Dalen A: An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Acta Neurochir 91: 60-6, 1988.
22. Yung WKA, Shapiro JR and Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42: 992-8, 1982.
23. Jordan JP, Hand CM, Markowitz RS and Black P: Test for chemotherapeutic sensitivity of cerebral gliomas: Use of colorimetric MTT assay. J Neuro-Oncol 14: 19-35, 1992.
24. Nikkhah G, Darling JL and Thomas GT: The application of the MTT chemosensitivity assay to short-term cell lines derived from gliomas: Characterization and comparison with a 35S-methionine uptake assay. Reg Cancer Treat 2: 112-8, 1989.
25. Nikkah G, Tonn JC, Hoffman O, Kraemer HP, Darling JL, Schonmayr R and Schachenmayr W: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I: Evaluation of test-specific variables. J Neuro-Oncol 13: 1-11, 1992.
26. Nikkhah G, Tonn JC, Hoffman O, Kraemer HP, Darling JL, Schachenmayr W and Schonmayr R: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient-and drug-specific variables. J Neuro-Oncol 13: 13-24, 1992.
27. Lee Y, Wikstrand CJ, Humphrey PA, Bigner SH, Friedman HS, Vrionis FD and Bigner DD: In vitro growth of brain tumors. In: Salcman M, ed. Neurobiology of Brain Tumors Volume 4: Concepts in Neurosurgery. Williams and Wilkins, p. 163-183, 1991.
28. Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Brodeur GM, He X, Wikstrand CJ, Kurtzberg J, Berens ME, Halperin EC and Bigner DD: Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Path 130: 472-84, 1988.
29. Fults D, Pedone CA, Morse HG, Rose JW and McKay RD: Establishment and characterization of a human primitive neuroectodermal tumor cell line from the cerebral hemisphere. J Neuropath Exp Neuro 51: 272-80, 1992.
30. He XM, Wikstrand CJ, Friedman HS, Bigner SH, Pleasure S, Trojanowski JQ and Bigner DD: Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. Lab Inves 64: 833-43, 1991.
31. Jacobsen PF, Jenkyn DJ and Papadimitriou JM: Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropath Exp Neuro 44: 472-85, 1985.
32. Pietsch T, Scharmann T, Fonatsch C, Schmidt D, Ockler R, Freihoff D, Albrecht S, Wiestler OD, Zeltzer P and Riehm H: Characterization of five new cell lines derived from human primitive neuroectodermal tumors of the central nervous system. Cancer Res 54: 3278-87, 1994.
33. Yamada M, Shimizu K, Tamura K, Okamoto Y, Matsui Y, Moriuchi S, Park K, Mabuchi E, Yamamoto K and Hayakawa T: Establishment and biological characterization of human medulloblastoma cell lines. Brain and Nerve 41:695-702, 1989.
34. Mikami T, Kurisu K, Kawamoto K, Kiya K, Mukada K, Hotta T, Ogasawara H, Sugiyama K and Uozumi T: Establishment and characterization of human medulloblastoma xenograft line. Hiroshima J Med Sc 40: 41-5, 1991.
35. White L, Sterling-Levis K, Pittman S, Tobias V and Sosula L: A xenograft model for the study of brain tumors. Cancer Ther Control 1: 213-24, 1990.
36. White L, Sterling-Levis K, Fisher R and Tobias V: Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model. J Neuro-Oncol 25: 39-47, 1995.
37. White L, Sterling-Levis K, Kees UR and Tobias V: Medulloblastoma/primitive neuroectodermal tumour studied as a Matrigel enhanced subcutaneous xenograft model. J Clin Neuroscience 8: 151-6, 2001.
38. Felker GM, Friedman HS, Dolan ME, Moschel RC and Schold C: Treatment of subcutaneous and intracranial brain tumor xenografts with 06-benzylguanine and 1,3-bis(2-chloroethyl)-1nitrosourea. Cancer Chemother Pharmacol 32: 471-6, 1993.
39. Schold SC Jr, Friedman HS, Bjornsson TD and Bigner DD: Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. Cancer Res 44: 2352-7, 1984.
40. Schuster JM, Friedman HS and Bigner DD: Therapeutic analysis of in vitro and in vivo brain tumor models. Neurologic Clinics 9: 375-82, 1991.
41. Vasquez-Lopez E: On the growth of Rous sarcoma inoculated into the brain. Am J Cancer 26: 29-55, 1936.
42. Walker DL, Padgett BL, ZuRhein GM, Albert AE and Marsh RF: Human papovavirus (JC): Induction of brain tumors in hamsters. Science 181: 674-6, 1973.
43. Mahaley MS Jr, Gentry RE and Bigner DD: Immunobiology of primary intracranial tumors. Part 2: The evaluation of chemotherapy and immunotherapy protocols using the avian sarcoma virus glioma model. J Neurosurg 47: 35-43, 1977.
44. Schold SC Jr and Bigner DD: A review of animal brain tumor models that have been used for therapeutic studies. In: Walker M, ed. Oncology of the Nervous System. Boston: Martinus-Nijhoff, p. 31-63, 1983.
45. Greene HSN: Heterologous transplantation of human and other mammalian tumors. Science 88: 357-8, 1938.
46. Greene HSN: The significance of the heterologous transplantability of human cancer. Cancer 5: 24, 1952.
47. Greene HSN: Heterotransplantation of tumors. Ann NY Acad Sci 69: 818-29, 1957.
48. Lemon HM, Lutz BR, Pope R, Parsons L, Handler AH and Patt DI: Survival and growth of human tissues transplanted to hamster cheek pouch. Science 115: 461-5, 1952.
49. Giovanella BC and Fogh J: The nude mouse in cancer research. In: Klein G, Weinhouse S, eds. Advances in Cancer Research, Vol 44. Academic Press, Inc, p. 69-120, 1985.
50. Braakhuis BJ, Nauta MM, Romijn JC, Rutgers DH and Smink T: Enhanced success rate of transplantation with human tumors in cyclophosphamide-treated nude mice. J Nat Cancer Inst 76: 241-5, 1986.
51. Horowitz ME, Phaham DM, Douglass EC, Kun LE, Houghton JA and Houghton PJ: Development and characterization of human ependymoma xenograft. HxBr5. Cancer Res 47: 499-504, 1987.
52. Nauta MM, Boven E, Schluper HM, Erkelens CA and Pinedo HM: Enhanced transplantability of human ovarian cancer lines in cyclophosphamide pretreated mice. Br J Cancer 54: 331-5, 1986.
53. McAllister RM, Isaacs H, Rongey R, Raer M, Au W, Soukup SW and Gardner MB: Establishment of a human medulloblastoma cell line. Int J Cancer 20: 206-12, 1977.
54. Flanagan SP: Nude, a new hairless gene with pleiotropic effects in the mouse. Genet Res 8: 295-309, 1966.
55. Takahashi Y, Shimizu A, Sakai T, Endo Y, Osawa N, Shisa H and Honjo T: Mapping of the nu gene using congenic nude strains and in situ hybridization. J Exp Med 175: 873-6, 1992.
56. Reth M: Immunodeficiency. Trapping the nude mouse gene. Current Biology 5: 18-20, 1995.
57. Pantelouris EM: Absence of thymus in a mouse mutant. Nature 217: 370-1, 1968.
58. Kopf-Maier P, Mboneko VF and Merker HJ: Nude mice are not hairless. Acta Anatomica 139: 178-90, 1990.
59. A report of the committee on care and use of the "nude" mouse. Guide for the care and use of the nude (thymus-deficient) mouse in biomedical research. Institute of Laboratory Animal Resources. Assembly of Life Sciences, National Research Council. ILAR News 19: M1-M20, 1976.
60. Hanna N, Davis TW and Fidler IJ: Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis. Int J Cancer 30: 371-6, 1982.
61. Sharp AK and Colston MJ: Elevated macrophage activity in nude mice. Exp Cell Biol 52: 44-7, 1984.
62. Sharp AK and Colston MJ: The regulation of macrophage activity in congenitally athymic mice. Euro J Immunol 14: 102-5, 1984.
63. Rygaard J and Povlsen CO: Heterotransplantation of a human malignant tumor to "nude" mice. Acta Pathologica et Microbiologica Scandinavica 77: 758-60, 1969.
64. Giovanella BC, Yim SO, Stehlin JS and Williams LJ: Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. J Nat Cancer Inst 48: 1531-3, 1972.
65. Crafts D and Wilson CB: Animal models of brain tumors. Nat Cancer Inst Monographs 46: 7-11, 1977.
66. Bogden AE, Houchens DP, Ovejera AA and Cobb WR: Advances in chemotherapy studies with the nude mouse. In: Fogh J, Giovanella BC, eds. The Nude Mouse in Experimental and Clinical Research. Academic Press Inc, p. 367-400, 1982.
67. Schold SC Jr, Bullard DE, Bigner SH, Jones TR and Bigner DD: Growth, morphology and serial transplantation of anaplastic human gliomas in athymic mice. J Neuro-Oncol 1: 5-14, 1983.
68. Rygaard J: Subcutaneous xenografts. In: Boven E, Winograd B, eds. The Nude Mouse in Oncology Research. CRC Press, p. 43-50, 1991.
69. Bradley NJ, Bloom HJ, Davies AJS and Swift SM: Growth of human gliomas in immunodeficient mice: A possible model for pre-clinical therapy studies. Br J Cancer 38: 263-72, 1978.
70. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW and Martin GR: Basement membrane complexes with biological activity. Biochemistry 25: 312-8, 1986.
71. Akbasak A, Toevs CC and Laske DW: Reconstituted basement membrane (matrigel) enhances the growth of human glioma cell lines in nude mice. J Neuro-Oncol 27: 23-30, 1996.
72. Mori T, Hikawa T, Yoshida T, Karashima A, Fujiki M and Hori S: The effect of Matrigel on the growth of glioma cells in vitro and in vivo. In: Tabuchi K, ed. Biological Aspects of Brain Tumors. Springer-Verlag, p. 416-420, 1990.
73. Wyrick BJ, Ozawa T, Lamborn KR, Bollen AW and Deen DF: Effects of Matrigel on the SF-767 malignant glioma athymic mouse tumor model. Anticancer Res 17: 2419-25, 1997.
74. Mullen P, Ritchie A, Langdon SP and Miller WR: Effect of Matrigen on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int J Cancer 67: 816-820, 1996.
75. Noel A, Simon N, Raus J and Foidart JM: Basement membrane components (matrigel) promote the tumorigenicity of human breast adenocarcinoma MCF7 cells and provide an in vivo model to assess the responsiveness of cells to estrogen. Biochem Pharmacol 43: 1263-7, 1992.
76. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG and Pretlow TP: Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res 51: 3814-7, 1991.
77. Albini A, Melchiori A, Garofalo A, Noonan DM, Basolo F, Taraboletti G, Chader GJ and Gavazzi R: Matrigel promotes retinoblastoma cell growth. Int J Cancer 52: 234-40, 1992.
78. Fridman R, Kibbe MC, Royce LS, Zain M, Sweeney M, Jicha DL, Yannelli JR, Martin GR and Kleinman HK: Enhanced tumor growth of both primary and established human and murine cells in athymic mice after coinjection with Matrigel. J Nat Cancer Inst 83: 769-74, 1991.
79. Sterling-Levis K, White L, Trickett AE, Gramacho C, Pittman SM and Tobias V: Heterotransplantation of early B-lineage acute lymphoblastic leukemia using a solubilized attachment matrix (Matrigel). Cancer Res 53: 1222-5, 1993.
80. Ishii E, Greaves A, Grunberger T, Freedman MH and Letarte M: Tumor formation by a human pre-B leukemia cell line in scid mice is enhanced by matrigel and is associated with induction of CD10 expression. Leukemia 9: 175-84, 1995.
81. Wikstrand CJ, Friedman HS and Bigner DD: Medulloblastoma cell-substrate interaction in vitro. Invasion and Metastasis 11: 310-24, 1991.
82. Bogden AE, Kelton DE, Cobb WR and Esber HJ: A rapid screening method for testing chemotherapeutic agents against human tumor xenografts. In: Houchens DP, Ovejera AA, eds. Proc Symp on the Use of Athymic (Nude) Mice in Cancer Research. p. 231-250, 1978.
83. Miyamichi K: Chemotherapy responsiveness of brain tumors in subrenal capsule assay. Hokkaido Igaku Zass 65: 41-9, 1990.
84. Weizsacker M, Nagamune A, Rathmer K and Wechsler W: Brain tumor growth and response to chemotherapy in the subrenal capsule assay. J Cancer Res Clin Oncol 106: 229-33, 1983.
85. Young HF, Merchant RE and Apuzzo MLJ: Immunocompetence of patients with malignant glioma. In: Salcman M, ed. Neurobiology of Brain Tumors, Volume 4: Concepts in Neurosurgery. Williams and Wilkins, p. 211-227, 1991.
86. Epstein AL, Herman MM, Kim H, Dorfman RF and Kaplan HS: Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse. Cancer 37: 2158-2176, 1976.
87. Giovanella BC, Nilsson K, Zech L, Klein G and Stehlin JS: Growth of diploid, Epstein-Barr virus-carrying human lymphoblastoid cell lines heterotransplantated into nude mice under immunologically privileged conditions. Int J Cancer 24: 103-13, 1979.
88. Kaye AH, Morstyn G, Gardner I and Pyke K: Development of a xenograft glioma model in mouse brain. Cancer Res 46: 1367-73, 1986.
89. Shapiro WR, Basler GA, Chernik NL and Posner JB: Human brain tumor transplantation into nude mice. J Nat Genet Inst 62: 447-53, 1979.
90. Houchens DP, Ovejera AA, Riblet SM and Slagel DE: Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 19: 799-805, 1983.
91. Schold SC Jr, Rawlings CE, Bigner SH and Bigner DD: Intracerebral growth of human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinolone, and cis-platinum. Neurosurg 12: 672-7, 1983.
92. Barker CF and Billingham RE: Immunologically privileged sites. Adv Immunol 25: 1-54, 1977.
93. Kaplan HJ, Streilen JW and Stevens TR: Transplantation immunology of the anterior chamber of the eye. J Immunol 115: 805-10, 1975.
94. Streilein JW: Anterior chamber associated immune deviation: The privilege of immunity in the eye. Surv Ophthalmol 35: 67-73, 1990.
95. Streilein JW and Cousins SW: Aqueous tumor factors and their effect on the immune response in the anterior chamber. Current Eye Res 9: 175-82, 1990.
96. Streilein JW, Wilbanks GA, Taylor A and Cousins S: Eye-derived cytokines and the immunosuppressive intraocular microenvironment: A review. Current Eye Res 11: 41-7, 1992.
97. Niederkorn J, Streilein JW and Shadduck JA: Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invet Ophthalmol Vis Sci 20: 355-63, 1981.
98. Croul S, Lublin FD, Del Valle L, Oshinsky RJ, Giordano A, Khalili K and Ritchie CK: The cellular response of JC virus T-antigen-induced brain tumor implants to a murine intra-ocular model. J Neuroimmunol 106: 181-8, 2000.
99. Gallie BL, Albert DM, Wong JJY, Buyukmihci N and Puliafito CA: Heterotransplantation of retinoblastoma into the athymic "nude" mouse. Invest Ophthalmol Vis Sci 16: 256-9, 1977.
100. Benedict WF, Lingua RW, Doiron DR, Dawson JA and Murphree AL: Tumor regression of human retinoblastoma in the nude mouse following photoradiation therapy. Med Paed Oncol 8: 397-401, 1980.
101. Gallie BL, Wong J, Ho L, Good R, Kitchin D and Ellsworth R: Athymic nude mouse model of retinoblastoma. Jpn J Opthalmol 22: 345-50, 1978.
102. White L, Gomer CJ, Doiron DR and Szirth BC: Ineffective photodynamic therapy (PDT) in a poorly vascularized xenograft model. Br J Cancer 57: 455-8, 1988.
103. White L, Reed C and Tobias V: Comparison of cyclophosphamide and diaziquone in a retinoblastoma xenograft model. Ophthalm Paediatr Genet 10: 99-105, 1989.
104. White L, Szirth BC and Benedict WF: Evaluation of response to chemotherapy in retinoblastoma heterotransplanted to the eyes of nude mice. Cancer Chemother Pharmacol 23: 63-7, 1989.
105. White L: Responsiveness of retinoblastoma to local diaziquone. Studies in a xenograft model. Invest Ophthalmol Vis Sci 31: 787-91, 1990.
106. White L, Meyer PR and Benedict WF: Establishment and characterisation of a human T-cell leukemia line (LALW-2) in nude mice. J Nat Cancer Inst 72: 1029-38, 1984.
107. White L, Haber M, Brian MJ, Norris MD, Trickett A, Sosula L, Tiley C and Stewart BW: Therapy-induced drug resistance in a human leukemia mice (LALW-2): A clinically relevant model. Cancer 39: 23-8, 1989.
108. White L: Establishment of leukaemic cell lines by xenografting. Cancer Forum 13: 59-60, 1989.
109. White L, Trickett A, Norris MD, Tobias V, Sosula L, Marshall GM and Stewart BW: Heterotransplantation of human lymphoid neoplasms using a nude mouse intraocular xenograft model. Cancer Res 50: 3078-86, 1990.
110. Bito LZ: The physiology and pathophysiology of intraocular fluids. Exp Eye Res 25: 273-89, 1977.
111. Davson H: The aqueous humour and intraocular pressure. In: Davson H, ed. Physiology of the Eye. London: Macmillam Press, p. 3-95, 1990.
112. Gardner SK: Ocular drug penetration and pharmacokinetic principles. In: Lamberts DW, Potter DE, eds. Clinical Ophthalmic Pharmacology. Boston, MA: Little, Brown and Co, p. 1-52, 1988.
113. Walker RW and Allen JC: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6: 62-6, 1988.
114. Allen J, Walker R, Lucks E, Jennings M, Barfoot S and Tan C: Carboplatin and recurrent childhood brain tumors. J Clin Oncol 5: 463, 1987.
115. Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, Falletta JM, Norris D, Ragab AH, Mahoney DH, Whitehead MV and Kun LE: Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin. A Pediatric Oncology Group randomized phase II study. J Clin Oncol 10: 249-56, 1992.
116. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD and Hammond GD: Carboplatin in childhood brain tumors. Cancer 66: 2465-8, 1990.
117. Rosenstock JG, Evans AE and Schut LJ: Response to vincristine of recurrent brain tumors in children. J Neurosurg 45: 135-40, 1976.
118. Chou F, Khan AH and Driscoll JS: Potential central nervous system antitumor agents: Aziridinylbenzoquinones II. J Med Chem 19: 1302-8, 1976.
119. Ettinger LJ, Ru N, Krailo M, Ruccione KS, Krivit W and Hammond GD: A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: A report from the Childrens Cancer Study Group. J Neuro-Oncol 9: 69-76, 1990.
120. Allen JC and Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55: 749-56, 1981.
121. Carpenter PA, White L, McCowage G, Nayanar V, Toogood I, Shaw PJ, Lockwood L and Tiedemann K: A dose intensive, cyclophosphamide-based regimen (VETOPEC) for relapsed progressive or advanced solid tumors of childhood: A report from the Australian and New Zealand Children's Cancer Study Group. Cancer 80: 489-96, 1997.
122. McCowage G, White L, Carpenter PA, Lockwood L, Toogood I, Tiedemann K and Shaw PJ: Granulocyte-macrophage colony-stimulating factor in association with high dose chemotherapy (VETOPEC) for childhood solid tumors: A report from the Australian and New Zealand Children's Cancer Study Group. Med and Ped Oncol 29: 108-14, 1997.
123. White L, Johnston H, Jones R, Mameghan H, Nayanar V, McWhirter W, Kellie S, Waters K and Toogood I: Postoperative chemotherapy without radiation in young children with malignant non-astrocytic brain tumors. A report from the Australia and New Zealand Childhood Cancer Study Group (ANZCCSG). Cancer Chemother Pharmacol 32: 403-6, 1993.
124. White L, McCowage G, Kannourakis G, Nayanar V, Colnan L, Kellie S, Shaw P, Seshadri R, Lockwood L and Tiedemann K: Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: A phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 12: 522-31, 1994.
125. Kiya K, Uozumi T, Ogasawara H, Sugiyama K, Hotta T, Mikami T and Kurisu K: Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 29: 339-42, 1992.
126. Friedman HS, Schold SC Jr, Mahaley MS Jr, Colvin OM, Oakes WJ, Vick NA, Burger PC, Bigner SH, Borowitz M and Halperin EC: Phase II treatment of medulloblastoma and pineoblastoma with melphalan: Clinical therapy based on experimental models of human medulloblastoma. J Clin Oncol 7: 904-11, 1989.
127. Allen JC, Walker R and Rosen G: Pre-radiation high-dose intravenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J Clin Oncol 6: 649-53, 1988.
128. Crafts D, Levin VA, Edwards MS, Pischer TL and Wilson CB: Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. J Neurosurg 49: 589-91, 1978.
129. Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC, Hilton J and Bigner DD: Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sufoxamine-mediated glutathione depletion. J Nat Cancer Inst 81: 524-7, 1989.
130. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakfield XO and Chiocca EA: Experimental tumor therapy in mice the cyclophosphamide-activating cytochrome P450 2B1 gene. Human Gene Ther 8: 969-78, 1994.
131. Chen L and Waxman DJ: Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55: 581-9, 1995.
132. Wei MX, Tamiya T, Rhee RJ, Breakfield XO and Chiocca EA: Diffusable cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy pradigm. Clin Cancer Res 1: 1171-7, 1995.
133. Friedman HS, Houghton PJ, Schold SC, Keir S and Bigner DD: Activity of 9-dimethylaminomethyl-10-hydroxycamptotecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171-4, 1994.
134. Friedman HS and Houghton PJ: Treatment of central nervous system xenografts with camptothecins. Ann NY Acad Sci 803: 210-2, 1996.
135. Vassal G, Boland I, Santos A, Bissery MC, Terrier-Lacombe MJ, Morizet J, Sainte-Rose C, Lellouch-Tubiana A, Kalifa C, and Gouyette A: Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 73: 156-63, 1997.
136. Cavazos CM, Keir ST, Yoshinari T, Bigner DD and Friedman HS: Therapeutic activity of the topoisomerase inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4 -c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 48: 250-4, 2001.
137. Plowman J, Waud WR, Koutsoukas AD, Rubinstein LV, Moore TD and Grever MR: Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-Bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54: 3799, 1994.
138. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, Bigner DD and Schold SC Jr: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55: 2853-7, 1995.
139. Maeda H, Uozumi T, Kurisu K, Matsuoka T, Kawamoto K, Kiya K, Ogasawara H, Sugiyama K, Mikami T and Monden S: Combined antitumor effects of TNF and G-CSF on a human medulloblastoma xenograft line. J Neuro-Oncol 21: 203-13, 1994.
140. Mikami T, Uozumi T, Kurisu K, Kawamoto K, Kiya K and Hotta T: In vivo effects of recombinant human lymphotoxin on human medulloblastoma xenograft: Enhancement of antitumor activity of etoposide. Biotherapy 8: 7-17, 1994.
141. Schabel FM, Trader MW, Laster WR Jr, Wheeler GP and Witt MH: Patterns of resistance and therapeutic synergysm among alkylating agents. Antibiotics and Chemother 23: 200-15, 1978.
142. Wang AM, Elion GB, Friedman HS, Bodell WJ, Bigner DD and Schold SC Jr: Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. Cancer Chemother Pharmacol 27: 278-84, 1991.
143. Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD and Schold SC Jr: Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Nat Cancer Inst 84: 1926-31, 1992.
144. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC and Janss AJ: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma model as single agent and in combination chemotherapy. Cancer Res 61: 1527-32, 2001.
145. Takada Y, Greig NH, Vistica DT, Rapoport SI and Smith OR: Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemother Pharmacol 29: 89-94, 1991.
146. Fekete I, Griffith OW, Schlageter KE, Bigner DD, Friedman HS and Groothuis DR: Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas. Cancer Res 50: 1251-6, 1990.
147. Cornford EM, Young D and Paxton JW: Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs. Cancer Chemother Pharmacol 29: 439-44, 1992.
148. Wowra B, Munkel K, Ullrich B, Semmler W and Zeller WJ: Human glioma xenografts: Characterization of chemotherapeutic investigators. In: Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Contributions to Oncology. Vol 42. Karger, p. 47-59, 1992.
149. Huang P, Allam A, Perez LA, Taghian A, Freeman J and Suit HD: The effects of combining recombinant human tumor necrosis factor-alpha with local radiation on tumor control probability of a human glioblastoma multiforme xenograft in nude mice. Int J Radiat Oncol Biol Phys 32: 93-8, 1995.
150. Williams JA, Edwards JA, Wessels BW, Dillehay LE, Wanek PM, Poggenburg JK, Wharam MD, Order SE and Klein JL: Targeting and therapy of human glioma xenografts in vivo using radiolabeled antibodies. Int J Radiat Oncol 19: 633-42, 1990.
151. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-2, 1992.
152. Ji Y, Powers SK, Brown JT, Walstad D and Maliner L: Toxicity of photodynamic therapy with photofrin in the normal rat brain. Lasers in Surgery & Medicine 14: 219-28, 1994.
153. Whelan HT, Kras LH, Ozker K, Bajic D, Schmidt MH, Liu Y, Trembath LA, Uzum F, Meyer GA and Segura AD: Selective incorporation of 111In-labeled PHOTOFRIN by glioma tissue in vivo. J Neuro-Oncol 22: 7-13, 1994.
154. Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM and Liu HB: Neutron capture therapy of the 9L rat gliosarcoma using the p-borono-phenylalanine-fructose complex. Int J Radiat Oncol Biol Phys 30: 643-52, 1994.
155. 10B-p-Boronophenylalanine-fructose and the boron neutron capture reaction on mouse brain dopaminergic neurons. Cancer Res 55: 874-7, 1995.
156. Colapinto EV, Zalutsky MR, Archer GE, Noska MA, Friedman HS, Carrel S and Bigner DD: Radioimmunotherapy of intracerebral human glioma xenografts with 131 I-labelled F(ab′)2 fragments of monoclonal antibody Mel-14. Cancer Res 50: 1822-7, 1990.
157. Wikstrand CJ, He XM, Fuller GN, Bigner SH, Fredman P, Svennerholm L and Bigner DD: Occurrence of lacto series gangliosides 3′-isoLM1 and 3′,6′-isoLD1 in human gliomas in vitro and in vivo. J Neuropath Exp Neuro 50: 756-69, 1991.
158. Fleshner M, Watkins LR, Redd JM, Kruse CA and Bellgrau D: A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplantation 4: 307-12, 1992.
159. Wen PY, Lampson MA and Lampson LA: Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: Implications for strategies of immunotherapy. J Neuroimmunol 36: 57-68, 1992.
160. Neuwelt EA, Barnett PA, Glasberg M and Frenkel EP: Pharmacology and neurotoxicity of cis-diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic blood-brain barrier modification. Cancer Res 43: 5278-85, 1983.
161. Neuwelt EA, Barnett PA, Barranger J, McCormick C, Pagel M and Frenkel E: Inability of dimethyl sulfoxide and 6-fluorouracil to open the blood-brain barrier. Neurosurg 12: 29-34, 1983.
162. Lee Y, Bullard DE, Wikstrand CJ, Zalutsky MR, Muhlbaier LH and Bigner DD: Comparison of monoclonal antibody delivery to intraveous and intracarotid administration. Cancer Res 47: 1941-6, 1987.
163. Blasberg RG, Nakagawa H, Bourdon MA, Groothuis DR, Patlak CS and Bigner DD: Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: Kinetics and implications for diagnosis and therapy. Cancer Res 47: 4432-4443, 1987.
164. Lee Y, Bullard DE, Humphrey PA, Colapinto EV, Friedman HS, Salutsky MR, Coleman RE and Bigner DD: Treatment of intracranial human glioma xenografts with 131 I-labelled anti-tenascin monoclonal antibody 81C6. Cancer Res 48: 2904-10, 1988.
165. Barth RF, Soloway AH and Fairchild RG: Boron neutron capture therapy of cancer. Cancer Res 50: 1061-70, 1990.
166. Coderre JA, Glass JD, Fairchild RG, Micca PL, and Fand I and Joel DD: Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res 50: 138-41, 1990.
167. Matalka KZ, Bailey MQ, Barth RF, Staubus AE, Soloway AH, Moeschberger ML, Coderre JA and Rofstad EK: Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. Cancer Res 53: 3308-313, 1993.
168. Ram Z, Culver KW, Walbridge S, Blaese RM and Oldfield EH: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53: 83-8, 1993.
169. Ross BD, Kim B and Davidson BL: Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Clin Cancer Res 1: 651-7, 1995.
170. Boviatsis EJ, Park Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO and Chiocca EA: Longterm survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54: 5745-51, 1994.
171. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL and Anderson WF: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Human Gene Ther 4: 39-69, 1993.
172. Isobe N, Uozumi T, Kurisu K and Kawamoto K: Experimental studies of the antitumor effect of TNP-470 on malignant brain tumors. Antitumor effect of TNP-470 on a human medulloblastoma xenograft line. Neuropediatrics 27: 136-42, 1996.